ArticleThe Journal of pharmacology and experimental therapeutics2026
Xylazine's κ relatively potent opioid agonist activity is not shared with other US Food and Drug Administration-approved α
Xi-Ping Huang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.